Aktis Oncology Prices Upsized IPO at $18.00 per Share, Raising $318 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16h ago
0mins
Source: Globenewswire
- IPO Pricing: Aktis Oncology has priced its upsized initial public offering at $18.00 per share, aiming to issue 17,650,000 shares and raise approximately $318 million, significantly enhancing its financial capacity in the oncology treatment sector.
- Underwriter Selection: The offering is managed by J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen, indicating strong market confidence in Aktis, which may provide robust support for its future growth.
- Trading Market: Aktis' stock is expected to begin trading on the Nasdaq Global Select Market on January 9, 2026, marking a significant milestone for the company in the capital markets and helping to elevate its brand recognition and market acceptance.
- Strategic Collaboration: Aktis' strategic partnership with Eli Lilly aims to leverage its unique miniprotein radioconjugate platform to develop novel radioconjugates, signaling the company's long-term potential in innovative drug development.
Analyst Views on AKTS
Wall Street analysts forecast AKTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 0.000
Low
Averages
High
Current: 0.000
Low
Averages
High
No data
About AKTS
ATech (Parent) Resolution Corp., formerly Akoustis Technologies, Inc., is not engaged in any business operating activity. The Company has no assets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
